论文部分内容阅读
目的探究依达拉奉治疗外伤性脑梗死的临床疗效和安全性。方法 72例颅脑外伤性脑梗死患者随机分为对照组36例和试验组36例。对照组患者给予降颅压、神经营养及改善微循环等常规治疗,试验组患者在此基础上予以静脉滴注依达拉奉注射液20 mL+0.9%NaCl 200 m L,bid,共14天。治疗后,对比2组患者的血液流变学变化情况,并依据格拉斯哥评分情况对2组患者的预后恢复情况进行评价,同时对临床用药安全性进行评价比较。结果试验组和对照组的总有效率分别为91.67%(33/36例)和72.22%(26/36例),差异均有统计学意义(均P<0.05)。治疗14天后,试验组和对照组的高切全血黏度分别为(4.73±0.56),(5.36±0.78)m Pa·s;低切全血粘度分别为(8.15±1.03),(9.54±1.26)mPa·s;血浆黏度分别为(1.41±0.15),(1.76±0.19)mPa·s;红细胞压积分别为(37.15±3.21)%,(43.17±4.03)%;纤维蛋白为分别为(3.58±0.45),(4.67±0.54)g·L~(-1),差异均有统计学意义(均P<0.05)。试验组的药物不良反应发生率为5.56%(1/36例),对照组为2.78%(2/36例),差异无统计学意义(P>0.05)。结论依达拉奉能够显著改善颅脑外伤脑梗死患者的血液流变学指标,其治疗效果优于常规神经外科治疗,对颅脑外伤脑梗死的临床治疗起到积极作用。
Objective To investigate the clinical efficacy and safety of edaravone in the treatment of traumatic cerebral infarction. Methods A total of 72 patients with craniocerebral traumatic cerebral infarction were randomly divided into control group (36 cases) and experimental group (36 cases). Patients in the control group were given conventional therapy such as intracranial pressure reduction, neurotrophic therapy and microcirculation improvement. Patients in the test group were treated with edaravone 20 ml and 0.9% NaCl 200 ml once daily for 14 days . After treatment, the changes of hemorheology were compared between the two groups, and the prognosis recovery of two groups was evaluated according to the Glasgow score. Meanwhile, the safety of clinical medication was evaluated and compared. Results The total effective rates of the experimental group and the control group were 91.67% (33/36 cases) and 72.22% (26/36 cases), respectively, with significant differences (all P <0.05). After 14 days of treatment, the high-cut whole blood viscosity of the experimental group and the control group were (4.73 ± 0.56) and (5.36 ± 0.78) m Pa · s, respectively. The low-cut whole blood viscosity were 8.15 ± 1.03 and 9.54 ± 1.26 ) mPa · s and plasma viscosity were (1.41 ± 0.15) and (1.76 ± 0.19) mPa · s, respectively. The hematocrit were (37.15 ± 3.21)% and (43.17 ± 4.03)%, respectively ± 0.45) and (4.67 ± 0.54) g · L -1, respectively (all P <0.05). The incidence of adverse drug reactions in the experimental group was 5.56% (1/36) and in the control group was 2.78% (2/36), the difference was not statistically significant (P> 0.05). Conclusion Edaravone can significantly improve the hemorrheological parameters in patients with cerebral infarction after traumatic brain injury. The therapeutic effect is better than that of conventional neurosurgical treatment, which plays a positive role in the clinical treatment of cerebral infarction.